Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-06-06
2004-02-10
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S283100
Reexamination Certificate
active
06689799
ABSTRACT:
The present invention relates to ester derivatives of 1,4-dihydropyridine-5-carboxylic acid with the general formula I,
wherein
R=CN, NO
2
or a —COOR′ group, wherein R′ represents a lower alkyl group;
R
1
=R
6
or R
4
;
R
2
=lower alkoxy or R
4
;
R
3
=H or R
4
;
R
4
=a coumarin group with formula II;
R
5
=H, lower alkyl, lower alkoxy, halogen, nitro, hydroxyl, or amino;
R
6
=H, lower alkyl, lower alkoxy, benzyloxy, cyano, nitro, carboxylic acid, optionally esterified with a lower alkanol, carboxamide, optionally substituted with 1-2 lower alkyl groups;
X a single bond, —(CH2)
n
—O—, of —(CH2)
m
—Y—(CH2)
k
—O, wherein n ranges from 1 to 6, m and k are each equal to or higher than 1 and the sum of m and k is smaller than or equal to 4; and
Y=phenylene, cycloalkylene, or a carbon atom substituted with 1 or 2 C
1-C
2
-alkyl groups;
with the provisio that lower alkyl, lower alkoxy, lower alkanol, benzyloxy, phenylene and cycloalkylene may optionally be substituted with 1-3 groups chosen from hydroxyl, cyano, amino, halogen, in particular chlorine or fluorine, and nitro;
under the condition that at least 1 of the groups R
1
, R
2
and R
3
is the same as R
4
, as well as the N-oxide, stereoisomers and/or addition salts thereof with a pharmaceutically acceptable acid or base;
where the term “lower alkyl” represents an optionally branched alkyl group having 1 to 6 carbon atoms, preferably 1 or 2 carbon atoms; the term “lower alkanol” represents a lower alkyl substituted with a hydroxyl group;
the term “lower alkoxy” represents an optionally branched alkoxy group having 1 to 6 carbon atoms, preferably 1 or 2 carbon atoms; and
the term “cycloalkyl” represents a cycloalkyl group having 3 to 8 carbon atoms.
It is remarked that more than 1 R
1
, R
5
, and R
6
groups may be present.
Halogen is to be understood as a halogen atom chosen from the group consisting of fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
BACKGROUND OF THE INVENTION
1. Field of the Invention (Technical Field)
The present invention relates to 1,4-dihydropyridine-5-carboxylic acid ester derivatives, method for the preparation thereof, and methods for the treatment of disease using such derivatives.
2. Background Art
The largest group of antiviral compounds known in the art are nucleoside-analogues. One significant disadvantage of nucleoside-analogues is that virus strains progressively develop resistance against them. Thus there is a need in the art for compounds having antiviral activity that are not nucleoside-analogues.
Coumarin derivatives have been described in the literature as having antiviral activity. For example, International Patent Application WO 92/18123 describes coumarin derivatives and closely related compounds such as alkoxycoumarin derivatives. It is indicated that these compounds are suitable for inhibiting the replication of retroviruses.
SUMMARY OF THE INVENTION (DISCLOSURE OF THE INVENTION)
The present invention relates to three methods for preparing an ester derivative of 1,4-dihydropyridine-5-carboxylic acid.
The present invention is characterized in that either
A. i) a coumarin derivative of the formula III
is converted to an acetoacetate-ester having the general formula IV;
ii) the acetoacetate-ester thus formed is reacted with a benzaldehyde having the formula V and an R′-aminocrotonate, wherein R′ is as defined before, yielding the desired ester derivative of 1,4-dihydropyridine-5-carboxylic acid; or,
B. i) a benzaldehyde derivative of the formula V,
wherein R
1
and R
6
are as defined before, is reacted with an R
2
-4-chloroacetoacetate, wherein R
2
is as defined before, yielding a benzylidene of the formula VI;
ii) the benzylidene formed in the previous step is reacted with an R′-3-aminocrotonate, wherein R′ is as defined before, yielding a 5-chloromethyl-1,4-dihydropyridine derivative of the formula VII;
iii) the 5-chloromethyl-1,4-dihydropyridine derivative formed in step ii) is reacted under basic conditions with a coumarin derivative of the formula III, where X and R
5
are as defined before, yielding the desired ester derivative of 1,4-dihydropyridine-5-carboxylic acid; or,
C. i) a coumarin derivative of the formula VIII;
where Z represents a leaving group and R
5
is as defined before, while A represents —(CH2)
n
—, or —(CH2)
m
—Y—(CH2)
k
— where n, m and k are as defined for X, are reacted under basic conditions with a benzaldehyde derivative of the formula V, where R
1
and R
6
have the meaning as defined before, yielding a Williamson ether of the formula IX;
ii) the Williamson ether is reacted with an R′-3-aminocrotonate derivative yielding the desired ester derivative of 1,4-dihydropyridine-5-carboxylic acid.
With respect to the method described under A, it is remarked that step A i) is conducted as described by Clemens R. J. et al. (J. Org. Chem. 50, pages 646-652, 1980). Step A. ii) concerns a Michael-addition reaction which is suitably performed in a polar solvent (such as methanol, ethanol or 2-propanol) and is described by Stout D. M. et al. (Chem. Rev. 82, pages 233-243, 1982).
With respect to the method described under B, it is remarked that the product (VI) obtained in step B i) does not have to be isolated, but can be condensated immediately in the subsequent step with the 3-aminocrotonate. The last step B. iii) concerns a preparation of a so-called Williamson ether ((Meerwein H., Methoden der Organischen Chemie (Houben Weyl) 6/3, p. 6-140).
Finally, with respect to the method described under C, it is remarked that step C i) concerns the preparation of a Williamson ether, which is performed under influence of a suitable base (such as potassium- or sodiumcarbonate, sodiumhydride, or triethylamine) in a polar inert solvent (for example methanol, acetone, dimethylformamide or dioxane). The second step C. ii) is again a Michael-addition, as described under step A. ii).
The present invention further relates to a pharmaceutical composition comprising a compound according to the invention together with a pharmaceutically acceptable carrier or excipient.
Finally, the present invention relates to a pharmaceutical composition containing an ester derivative of 1,4-dihydropyridine-5-carboxylic acid according to the invention as the active compound, suitable for the treatment of a viral affliction, high blood pressure or glaucoma.
The viral afflictions may be such viral afflictions caused by:
1 Adenovirus type 2
2 Coxsackie virus B4
3 Cytomegalovirus (AD-169 strain; Davis strain)
4 Herpes simplex virus 1 (KOS; F; McIntyre; TK-B2006; TK-VMW1837; TK-Cheng C158/77; TK-Field C137/101)
5 Herpes simplex virus-2 (G; 196; Lyons)
6 HIV-1
7 HIV-2
8 Influenza virus A
9 Influenza virus B
10 Parainfluenza-3 virus
11 Polio virus-1
12 Reovirus
13 Respiratory syncytial virus
14 Semliki forest virus
15 Sindbis virus
16 Vaccinia virus
17 Varicella zoster virus (TK
+
OKA strain; TK
+
YS strain; TK
−
07/1 strain; TK
−
YS/R strain;
18 Vesicular stomatitus virus.
REFERENCES:
patent: 4564619 (1986-01-01), Tanaka et al.
patent: 5545646 (1996-08-01), Straub et al.
patent: 5721248 (1998-02-01), Straub et al.
patent: 0194750 (1986-09-01), None
patent: 0 194 750 (1986-09-01), None
patent: 2127402 (1984-04-01), None
patent: WO 92 18132 (1992-10-01), None
Sterk Geert Jan
Van Der Werf Jan Fetze
Rephartox
Seaman D. Margaret
Slusher Stephen A.
LandOfFree
1,4-dihydropyridine-5-carboxylic acid ester derivatives and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4-dihydropyridine-5-carboxylic acid ester derivatives and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4-dihydropyridine-5-carboxylic acid ester derivatives and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3324458